FastForward Innovations Ltd, the AIM quoted company focusing on making investments in fast growing and industry leading businesses, is pleased to note that Little Green Pharma Ltd (‘LGP’) has today announced that it will be exclusively supplying medicinal cannabis oil products to enrolled patients as well as providing funding for study costs for the QUality of life Evaluation STudy (“The QUEST Initiative”).
The QUEST Initiative, which is being conducted by researchers at the University of Sydney, aims to be one of the world’s largest longitudinal studies investigating the quality of life and health economics on patients with chronic disease prescribed medicinal cannabis. FastForward has a 0.9% interest in the issued stock of LGP.
Ed McDermott, CEO of FastForward Innovations, commented: “Little Green Pharma is one of our newest investments in the medical cannabis space and we are delighted that it is already delivering such strong newsflow. The QUEST Initiative aims to have at least 2,100 patients by 30 June 2021, which is a very significant number, and it is excellent to hear that Little Green Pharma is involved with the exclusive supply of medical cannabis oil products as well as providing funding for study costs. We look forward to providing updates as the study progresses.”
The announcement is set out below without material changes or adjustments other than for the inclusion of links and can be viewed in full on LGP’s website via the following link: https://investor.littlegreenpharma.com/site/PDF/9f6a7d18-b9ad-4d67-b892-c630bf7f9727/LargeScaleCannabisStudyLaunched
LARGE SCALE CANNABIS STUDY LAUNCHED
18 FEBRUARY 2021
Little Green Pharma Ltd (ASX: LGP, “LGP” or the “Company”) wishes to advise of the media release issued today by the University of Sydney relating to the QUality of life Evaluation STudy (“The QUEST Initiative”).
The QUEST Initiative aims to be one of the world’s largest longitudinal studies investigating the quality of life and health economics on patients with chronic disease prescribed medicinal cannabis.
LGP will exclusively supply medicinal cannabis oil products to enrolled patients as well as providing funding for study costs.
The study, conducted by researchers at the University of Sydney, is for a two-year period and aims to recruit at least 2,100 patients by 30 June 2021. It also has the potential to be extended internationally.
Please see the Little Green Pharma announcement for details of the study which can be found in an attached media release from the University of Sydney.
ASX ANNOUNCEMENT LGP TO EXCLUSIVELY SUPPLY CANNABIS MEDICINES TO WIDE-RANGING QUALITY OF LIFE STUDY ENDS FOR MORE INFORMATION, PLEASE CONTACT:
About Little Green Pharma
Little Green Pharma is a vertically integrated medicinal cannabis business with operations from cultivation and production through to manufacturing and distribution.
The Company has an indoor cultivation facility and manufacturing facility in Western Australia for the production of its own-branded range of GMP-grade medicinal cannabis products.
Little Green Pharma products comply with all required Therapeutic Goods Administration regulations and testing requirements. With a growing range of products containing differing ratios of active ingredients, Little Green Pharma supplies medical-grade cannabis products to Australian and overseas markets.
The Company has a strong focus on patient access in the emerging global medicinal cannabis market and is actively engaged in promoting education and outreach programs, as well as participating in clinical investigations and research projects to develop innovative new delivery systems.
For more information about Little Green Pharma go to www.littlegreenpharma.com
If anyone reads this article found it useful, helpful? Then please subscribe www.share-talk.com or follow SHARE TALK on our Twitter page for future updates.
Terms of Website Use
All information is provided on an as-is basis. Where we allow Bloggers to publish articles on our platform please note these are not our opinions or views and we have no affiliation with the companies mentioned